Brief: Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications
07/12/2021 13:05
Dec 7 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES REPORTS POSITIVE TOPLINE PHASE 1
DATA ON
LEAD THERAPEUTIC CANDIDATE PRA023; EXPANDS INDICATIONS TO
INCLUDE SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
(SSC-ILD)
* PROMETHEUS BIOSCIENCES - PRA023 PHASE 1 TRIAL ACHIEVED
PRIMARY
OBJECTIVE OF SAFETY AND TOLERABILITY, DEMONSTRATED FAVORABLE
OUTCOMES ON KEY ENDPOINTS
* PROMETHEUS BIOSCIENCES INC - RECEIVED CLEARANCE FROM FDA
FOR NEW
IND APPLICATION IN SSC-ILD, PLANS TO INITIATE ATHENA-SSC-ILD
PHASE 2 TRIAL IN Q1 2022
Source text for Eikon: ID:nGNX2k4jrk
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results